TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 47nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 11.6nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 80.5nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 387nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 53.6nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 7.05E+3nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 142nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 2.40nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 90.3nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 43.4nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 324nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 6.80nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 9.30nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 8.40nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 15.3nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 10.1nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 20.7nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 22.3nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 9.40nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 11.9nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 13nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 8.80nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 55.5nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 47.9nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 61.8nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 69.1nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 52.2nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 53.7nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 89.5nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 65.4nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 25.8nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 166nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 5.5nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 36.3nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 9nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 9.5nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 10.9nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 50.7nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 51.8nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 6.10nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 51.6nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 6.80nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 43.4nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 20.4nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 183nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 127nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 1.20nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 11.6nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 466nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 group M subtyp...)
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 95.9nMAssay Description:Jurkat HIV-luciferase clones were maintained in RPMI medium 1640 (Gibco by Life Technologies) containing 10% (vol/vol) fetal bovine serum (SAFC/Sigma...More data for this Ligand-Target Pair